EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Zin W Myint, Giuseppe Fornarini, Thomas Buttner und 19 weitere

Cancer Immunology, Immunotherapy · 09.05.2025 · 74 (7)

DOI: 10.1007/s00262-025-04019-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 09.05.2025. Verfasst von Camillo Porta und 30 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Department of Medicine, University of Bari "A. Moro", Bari, Italy. camillo.porta@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Phenylurea Compounds, Quinolines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pembrolizumab plus lenvatinib is a treatment option for metastatic Renal Cell Carcinoma (mRCC). In the ARON-1 study we investigated we the real-world experiences gained from the use of this combination for mRCC. METHODS: We retrospectively investigated real-world clinical outcomes of mRCC patients receiving pembrolizumab plus lenvatinib within the ARON-1 study. Overall survival (OS) was calculated from the start of pembrolizumab plus lenvatinib to death for any cause. Progression-Free Survival (PFS) was defined as the time from the start of pembrolizumab to progression or death from any cause. Duration of response (DoR) was defined as the time from the start of pembrolizumab to disease progression or death, whichever occurred first, in patients who achieved complete remission (CR) or partial response (PR). Overall Response Rate (ORR) was defined as the proportion of patients who achieve a CR or PR per RECIST criteria. Adverse events were retrospectively collected from electronic and paper charts and categorized by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. RESULTS: Overall, we included 202 mRCC patients treated with pembrolizumab plus lenvatinib. The median follow-up time was 15.1 months. The median OS was not reached (NR), with a median PFS of 25.6 months and an Overall Response Rate (ORR) of 59%. The median Duration of Response (DoR) was 26.2 months. G3-G4 adverse events (AEs) were observed in 92 patients (46%), with hypertension being the most common AE (13%). CONCLUSIONS: Pembrolizumab plus lenvatinib is an effective and tolerable treatment for mRCC also in the real-world setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, HumanizedKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

ARON- 1Immune-combinationsLenvatinibPembrolizumabReal-world dataRenal cell carcinomaSurvival

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Interdisciplinary Department of Medicine, University of Bari "A. Moro", Bari, Italy. camillo.porta@gmail.com.
  • Division of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Piazzale G. Cesare 11, 70124, Bari, Italy. camillo.porta@gmail.com.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Royal Marsden NHS Foundation Trust, London, UK.
  • Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.

Förderung

  • NCI NIH HHS

Zitieren

APA

Porta, C., Massari, F., Taha, T., Grande, E., Bourlon, M. T., Kanesvaran, R., Basso, U., Molina-Cerrillo, J., Alonso-Gordoa, T., Myint, Z. W., Fornarini, G., Buttner, T., Park, S. H., Ürün, Y., De Giorgi, U., Pichler, R., Rescigno, P., Buchler, T., Studentova, H., …, & Santoni, M. (2025). Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study. Cancer Immunology, Immunotherapy, 74(7). https://doi.org/10.1007/s00262-025-04019-x

Vancouver

Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, et al. Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study. Cancer Immunology, Immunotherapy. 2025;74(7). doi:10.1007/s00262-025-04019-x

BibTeX
@article{Porta2025,
  author = {Porta, Camillo and Massari, Francesco and Taha, Tarek and Grande, Enrique and Bourlon, Maria T and Kanesvaran, Ravindran and Basso, Umberto and Molina-Cerrillo, Javier and Alonso-Gordoa, Teresa and Myint, Zin W and Fornarini, Giuseppe and Buttner, Thomas and Park, Se Hoon and Ürün, Yüksel and De Giorgi, Ugo and Pichler, Renate and Rescigno, Pasquale and Buchler, Tomas and Studentova, Hana and Melichar, Bohuslav and Ansari, Jawaher and Mollica, Veronica and Kucharz, Jakub and Rizzo, Mimma and Rizzo, Alessandro and Kopp, Ray Manneh and Buti, Sebastiano and Monteiro, Fernando Sabino Marques and Soares, Andrey and Bamias, Aristotelis and Santoni, Matteo},
  title = {Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {7},
  doi = {10.1007/s00262-025-04019-x}
}
Kostenlos starten →